These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

331 related articles for article (PubMed ID: 26453696)

  • 1. Effects of Blocking D2/D3 Receptors on Mismatch Negativity and P3a Amplitude of Initially Antipsychotic Naïve, First Episode Schizophrenia Patients.
    Düring S; Glenthøj BY; Oranje B
    Int J Neuropsychopharmacol; 2015 Oct; 19(3):pyv109. PubMed ID: 26453696
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Frontal fasciculi and psychotic symptoms in antipsychotic-naive patients with schizophrenia before and after 6 weeks of selective dopamine D2/3 receptor blockade.
    Ebdrup BH; Raghava JM; Nielsen MØ; Rostrup E; Glenthøj B
    J Psychiatry Neurosci; 2016 Mar; 41(2):133-41. PubMed ID: 26599135
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of dopamine D2/D3 blockade on human sensory and sensorimotor gating in initially antipsychotic-naive, first-episode schizophrenia patients.
    Düring S; Glenthøj BY; Andersen GS; Oranje B
    Neuropsychopharmacology; 2014 Dec; 39(13):3000-8. PubMed ID: 24954063
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selective attention and mismatch negativity in antipsychotic-naïve, first-episode schizophrenia patients before and after 6 months of antipsychotic monotherapy.
    Oranje B; Aggernaes B; Rasmussen H; Ebdrup BH; Glenthøj BY
    Psychol Med; 2017 Sep; 47(12):2155-2165. PubMed ID: 28443529
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Striatal D(2/3) Binding Potential Values in Drug-Naïve First-Episode Schizophrenia Patients Correlate With Treatment Outcome.
    Wulff S; Pinborg LH; Svarer C; Jensen LT; Nielsen MØ; Allerup P; Bak N; Rasmussen H; Frandsen E; Rostrup E; Glenthøj BY
    Schizophr Bull; 2015 Sep; 41(5):1143-52. PubMed ID: 25698711
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Two subgroups of antipsychotic-naive, first-episode schizophrenia patients identified with a Gaussian mixture model on cognition and electrophysiology.
    Bak N; Ebdrup BH; Oranje B; Fagerlund B; Jensen MH; Düring SW; Nielsen MØ; Glenthøj BY; Hansen LK
    Transl Psychiatry; 2017 Apr; 7(4):e1087. PubMed ID: 28398342
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sensorimotor gating and habituation of the startle response in schizophrenic patients randomly treated with amisulpride or olanzapine.
    Quednow BB; Wagner M; Westheide J; Beckmann K; Bliesener N; Maier W; Kühn KU
    Biol Psychiatry; 2006 Mar; 59(6):536-45. PubMed ID: 16139819
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Longitudinal associations between mismatch negativity and disability in early schizophrenia- and affective-spectrum disorders.
    Kaur M; Lagopoulos J; Lee RS; Ward PB; Naismith SL; Hickie IB; Hermens DF
    Prog Neuropsychopharmacol Biol Psychiatry; 2013 Oct; 46():161-9. PubMed ID: 23851120
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Associations between P3a and P3b amplitudes and cognition in antipsychotic-naïve first-episode schizophrenia patients.
    Kruiper C; Fagerlund B; Nielsen MØ; Düring S; Jensen MH; Ebdrup BH; Glenthøj BY; Oranje B
    Psychol Med; 2019 Apr; 49(5):868-875. PubMed ID: 29914589
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antagonist and partial agonist at the dopamine D2 receptors in drug-naïve and non-drug-naïve schizophrenia: a randomized, controlled trial.
    Takekita Y; Fabbri C; Kato M; Nonen S; Sakai S; Sunada N; Koshikawa Y; Wakeno M; Okugawa G; Kinoshita T; Serretti A
    Eur Arch Psychiatry Clin Neurosci; 2015 Oct; 265(7):579-88. PubMed ID: 26016467
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MMN/P3a deficits in first episode psychosis: comparing schizophrenia-spectrum and affective-spectrum subgroups.
    Kaur M; Battisti RA; Ward PB; Ahmed A; Hickie IB; Hermens DF
    Schizophr Res; 2011 Aug; 130(1-3):203-9. PubMed ID: 21550211
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduced P3a amplitudes in antipsychotic naïve first-episode psychosis patients and individuals at clinical high-risk for psychosis.
    Mondragón-Maya A; Solís-Vivanco R; León-Ortiz P; Rodríguez-Agudelo Y; Yáñez-Téllez G; Bernal-Hernández J; Cadenhead KS; de la Fuente-Sandoval C
    J Psychiatr Res; 2013 Jun; 47(6):755-61. PubMed ID: 23507048
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is regionally selective D2/D3 dopamine occupancy sufficient for atypical antipsychotic effect? an in vivo quantitative [123I]epidepride SPET study of amisulpride-treated patients.
    Bressan RA; Erlandsson K; Jones HM; Mulligan R; Flanagan RJ; Ell PJ; Pilowsky LS
    Am J Psychiatry; 2003 Aug; 160(8):1413-20. PubMed ID: 12900302
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Auditory Mismatch Negativity and P300a Elicited by the "Optimal" Multi-feature Paradigm in Early Schizophrenia.
    Fisher DJ; Campbell DJ; Abriel SC; Ells EML; Rudolph ED; Tibbo PG
    Clin EEG Neurosci; 2018 Jul; 49(4):238-247. PubMed ID: 29502452
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Frontal D2/3 Receptor Availability in Schizophrenia Patients Before and After Their First Antipsychotic Treatment: Relation to Cognitive Functions and Psychopathology.
    Nørbak-Emig H; Ebdrup BH; Fagerlund B; Svarer C; Rasmussen H; Friberg L; Allerup PN; Rostrup E; Pinborg LH; Glenthøj BY
    Int J Neuropsychopharmacol; 2016 May; 19(5):. PubMed ID: 26819282
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Amisulpride a selective dopamine antagonist and atypical antipsychotic: results of a meta-analysis of randomized controlled trials.
    Leucht S
    Int J Neuropsychopharmacol; 2004 Mar; 7 Suppl 1():S15-20. PubMed ID: 14972080
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Validation of mismatch negativity and P3a for use in multi-site studies of schizophrenia: characterization of demographic, clinical, cognitive, and functional correlates in COGS-2.
    Light GA; Swerdlow NR; Thomas ML; Calkins ME; Green MF; Greenwood TA; Gur RE; Gur RC; Lazzeroni LC; Nuechterlein KH; Pela M; Radant AD; Seidman LJ; Sharp RF; Siever LJ; Silverman JM; Sprock J; Stone WS; Sugar CA; Tsuang DW; Tsuang MT; Braff DL; Turetsky BI
    Schizophr Res; 2015 Apr; 163(1-3):63-72. PubMed ID: 25449710
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prolactinemia is uncoupled from central D2/D3 dopamine receptor occupancy in amisulpride treated patients.
    Bressan RA; Erlandsson K; Spencer EP; Ell PJ; Pilowsky LS
    Psychopharmacology (Berl); 2004 Sep; 175(3):367-73. PubMed ID: 14997280
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vivo extrastriatal and striatal D2 dopamine receptor blockade by amisulpride in schizophrenia.
    Xiberas X; Martinot JL; Mallet L; Artiges E; Canal M; Loc'h C; Mazière B; Paillère-Martinot ML
    J Clin Psychopharmacol; 2001 Apr; 21(2):207-14. PubMed ID: 11270918
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Attenuated mismatch negativity in patients with first-episode antipsychotic-naive schizophrenia using a source-resolved method.
    Randau M; Oranje B; Miyakoshi M; Makeig S; Fagerlund B; Glenthøj B; Bak N
    Neuroimage Clin; 2019; 22():101760. PubMed ID: 30927608
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.